| Stivarga (regorafenib) / Bayer |
2021-005339-22: To evaluate the efficacy and safety of regorafenib in patients with refractory primary bone tumors. Ocena skuteczności i bezpieczeństwa zastosowania regorafenibu u pacjentów z opornymi na leczenie pierwotnymi nowotworami kości. |
|
|
| Not yet recruiting | 2 | 30 | Europe | Tablet, Stivarga 40 mg | Instytut Matki i Dziecka, Medical Research Agency | Refractory primary bone tumors, Refractory primary bone tumors, Diseases [C] - Cancer [C04] | | | | |
ACTRN12616001187437: Molecular Profiling and Matched Targeted Therapy for Patients with Metastatic Melanoma (MatchMel) |
|
|
| Not yet recruiting | 2 | 1000 | | | Melanoma Institute Australia, Melanoma Institute Australia, National Health and Medical Research Council | Metastatic Melanoma | | | | |
2015-001105-13: Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, single-arm, two-stage, phase 2 study. Regorafenib in monoterapia come trattamento di seconda linea di pazienti affetti da carcinoma colorettale con mutazioni di RAS: studio mutlicentrico di fase 2, a singolo braccio, a due stadi. |
|
|
| Ongoing | 2 | 46 | Europe | regorafenib, Film-coated tablet, STIVARGA - 40 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 28 COMPRESSE | ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, Bayer | patients with RAS-mutant advanced colorectal cancer pazienti affetti da carcinoma colorettale con mutazioni di RAS, patients with RAS-mutant advanced colorectal cancer pazienti affetti da carcinoma colorettale con mutazioni di RAS, Diseases [C] - Cancer [C04] | | | | |
2015-002629-21: Phase II study on Regorafenib in advanced Solitary Fibrous Tumor Studio di fase 2 su Regorafenib nel tumore fibroso solitario avanzato |
|
|
| Ongoing | 2 | 20 | Europe | stivarga, BAY 73-4506, Tablet, STIVARGA - 40 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 28 COMPRESSE | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | Solitary Fibrous Tumor tumore fibroso solitario, Solitary Fibrous Tumor tumore fibroso solitario, Diseases [C] - Cancer [C04] | | | | |
2014-004927-27: A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer. |
|
|
| Ongoing | 2 | 15 | Europe | Stigvarga, Stigvarga | Med. Univ. Wien, Innere Med. I | non-resectable pretreated colorectal cancer | | | | |
2015-001298-42: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST) |
|
|
| Ongoing | 2 | 240 | Europe, RoW | Imatinib, Regorafenib, Tablet, Stivarga | European Organisation for Research and Treatment of Cancer, European Organisation for Research and Treatment of Cancer (EORTC), EORTC AISBL/IVZW, Bayer, AGITG, EORTC | unresectable metastatic GIST, gastrointestinal stromal tumour (GIST -, a cancer of the stomach and bowel) that has spread and cannot be surgically removed, Diseases [C] - Cancer [C04] | | | | |
2012-000709-59: A study to assess if regorafenib when given in combination with standard chemotherapy (FOLFIRI) will result in increased survival, without the cancer getting worse, as compared to a non-active treatment (placebo) given in combination with standard chemotherapy (FOLFIRI). The study will be conducted in a sub-group of metastatic colorectal cancer patients who have failed on their 1st oxaliplatin containing chemotherapy regimen. |
|
|
| Ongoing | 2 | 60 | Europe | Regorafenib, Fluorouracil, Irinotecan Hydrochloride, Leucovorin, BAY 73-4506, | The Irish Clinical Oncology Research Group, ICORG (the all-Ireland Cooperative Oncology Research Group), Bayer HealthCare Pharmaceuticals INC | Second-Line Therapy in Patients with Metastatic Colorectal Cancer. | | | | |
ReDOS, NCT02368886: Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 123 | US | Clobetasol Propionate, Olux-E, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, Stivarga | Academic and Community Cancer Research United, National Cancer Institute (NCI) | Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7 | 09/17 | 03/23 | | |
ACTRN12614000950662: A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST) |
|
|
| Active, not recruiting | 2 | 76 | | | Australasian Gastro-Intestinal Trials Group (AGITG) , Bayer Global | Metastatic gastrointestinal stromal tumour (GIST) | | | | |
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 152 | RoW | Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA) | Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer | Solid Tumors, Colorectal Cancer | 04/18 | 09/18 | | |
2017-003653-42: Study to assess efficacy and safety of the medication named Idarubicin given orally every other day to patients with advanced tumor of the liver who progressed or are intoelrant to the medication Sorafenib and Regorafenib Studio che valuta l’efficacia e la sicurezza del farmaco Idarubicina dato oralmente a giorni alterni in pazienti affetti da tumore del fegato avanzato che non rispondono più al trattamento o hanno presentato intolleranza al farmaco Sorafenib e Regorafenib |
|
|
| Ongoing | 2 | 47 | Europe | Zavedos, 027441031, Capsule, hard, ZAVEDOS - 5 MG CAPSULE RIGIDE FLACONE DA 1 CAPSULA | CENTRO DI RIFERIMENTO ONCOLOGICO, CRO Aviano IRCCS | Patients with interemdiate-advanced stage hepatocarcinoma Pazienti affetti da epatocarcinoma allo stadio intermedio-avanzato, Patients with tumor of the liver Pazienti affetti da tumore del fegato, Diseases [C] - Digestive System Diseases [C06] | | | | |
2019-003108-10: Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma progressing under sorafenib Regorafenib seguido del Nivolumab en pacientes con progresión de la enfermedad tratados con sorafenib |
|
|
| Not yet recruiting | 2 | 60 | Europe | REGORAFENIB, NIVOLUMAB, REGORAFENIB, NIVOLUMAB, Tablet, Concentrate for solution for infusion, SITVARGA, OPDIVO | Fundació Clinic per a la Recerca Biomèdica, BAYER | Hepatocellular carcinoma Carcinoma hepatocelular, Hepatocellular carcinoma Carcinoma hepatocelular, Diseases [C] - Cancer [C04] | | | | |
2019-004196-39: A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer |
|
|
| Not yet recruiting | 2 | 340 | Europe | Regorafenib, trifluridine/tipiracil, L01XE21, Tablet, Stivarga, LONSURF - 15 MG/6,14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER AL/AL - 20 COMPRESSE | UNICANCER, Bayer HealthCare Pharmaceuticals Inc. | The study population will consist of male and female patients aged ≥ 18 years old with metastatic colorectal cancer after failure of fluoropyrimidine-, irinotecan-, and oxaliplatin-based chemotherapies, as well as EGFR and VEGF inhibitors in patients eligible for these treatments., metastatic colorectal cancer after failure of fluoropyrimidine-, irinotecan-, and oxaliplatin-based chemotherapies, as well as EGFR and VEGF inhibitors in patients eligible for these treatments., Diseases [C] - Cancer [C04] | | | | |
2020-002344-23: Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer carcinomaAn open-label phase II Régorafenib en association avec une polychimiothérapie métronomique à base de cyclophosphamide, capecitabine et aspirine à faible dose dans le traitement des cancers colorectaux métastatiques. Etude de phase II |
|
|
| Ongoing | 2 | 49 | Europe | Régorafenib, Cyclophosphamide métronomique, Capécitabine, Aspirine, Coated tablet, Tablet, Powder for oral solution, STIVARGA, Cyclophosphamide métronomique, Xeloda, Kardégic | CHU de Besançon, BAYER | Metastatic colorectal cancer Cancer colorectal métastatique, Metastatic colorectal cancer Cancer colorectal métastatique, Diseases [C] - Cancer [C04] | | | | |
2021-000252-18: Evaluation of the personalised treatment of colorectal cancer by regorafenib based on therapeutic and pharmacological monitoring Évaluation de la personnalisation du traitement par régorafenib basée sur son dosage sanguin chez les patients atteints d'un cancer colorectal métastatique |
|
|
| Not yet recruiting | 2 | 100 | Europe | regorafenib, Tablet, Stivarga | Rennes University Hospital, BAYER HEALTHCARE | metastatic colorectal cancer cancer colorectal métastatique, metastatic colorectal cancer cancer colorectal métastatique, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 15 | Europe | regorafenib, Stivarga | Grupo Espanol de Investigacion en Sarcomas, Bayer | Gastrointestinal Stromal Tumors | 08/21 | 08/21 | | |
REGOVAR, NCT02584465: REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression |
|
|
| Completed | 2 | 68 | Europe | Tamoxifen, Regorafenib | ARCAGY/ GINECO GROUP, Bayer | Ovarian Carcinoma | 09/21 | 09/21 | | |
2020-001588-10: Adjuvant therapy in stage IV colorectal cancer patients NED terapia adiuvante nei pazienti con adenocarcinoma del colon-retto in stadio IV NED |
|
|
| Not yet recruiting | 2 | 170 | Europe | DURVALUMAB, REGORAFENIB (STIVARGA), [EMEA/H/C/4771], [BAY 73-4506], Concentrate for solution for injection/infusion, Modified-release tablet, STIVARGA | IRCCS-A.O.U. SAN MARTINO-IST, AIRC, Astra Zeneca, Bayer | stage IV colorectal cancer patients with no evidence of disease (NED) nei pazienti con adenocarcinoma del colon-retto in stadio IV senza evidenza di malattia (NED), colorectal adenocarcinoma adenocarcinoma del colon retto, Diseases [C] - Cancer [C04] | | | | |
ChiCTR2000040139: A prospective study of the efficacy and safety of tislelizumab combined with regorafenib in patients with unresectable or recurring cholangiocarcinoma after resection |
|
|
| Not yet recruiting | 2 | 42 | China | regorafenib + tislelizumab | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology ; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Beijing Association of Cancer Prevention and Treatment | Cholangiocarcinoma | | | | |
2021-000689-14: Finnish national phase 2 study to evaluate targeted drug treatment in advanced cancer. Yksilöllistä syövänhoitoa selvittävä kansallinen vaiheen 2 lääketutkimus edenneessä syövässä. |
|
|
| Not yet recruiting | 2 | 250 | Europe | abemaciclib, pralsetinib, Tablet, Capsule, hard, Injection, Infusion, Capsule, Stivarga, Alecensa, Cotellic, Erivedge, Phesgo, Rozlytrek, Tecentriq, Zelboraf, Verzenios, Retsevmo, Erleada, Tafinlar, Mekinist, Gavreto, Lynparza | Helsinki University Hospital, Helsinki University Hospital | Patients with an advanced solid tumor for which standard treatment options no longer exist and with acceptable performance status and organ function with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test., Patients with advanced cancer where standard treatment options no longer exist. Potilaat, jotka sairastava edennyttä syöpää, johon tavanomaiset hoitolinjat eivät enää tehoa., Diseases [C] - Cancer [C04] | | | | |
ChiCTR1900027398: A prospective, non-interventional, multicenter clinical study to explore the efficacy and safety of camrelizumab in combination with regorafenib in patients with advanced colorectal cancer |
|
|
| Recruiting | 2 | 43 | | Drug intervention | The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Zhejiang University, Company funding | Colorectal cancer | | | | |
ChiCTR2000040036: Regorafenib combined with PD-1 monoclonal antibody in the treatment of patients with unresectable hepatocellular carcinoma: a single-arm, prospective, multicenter study |
|
|
| Recruiting | 2 | 50 | | regorafenib + PD-1 monoclonal antibody | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Chen Xiaoping Technology Development Foundation；Wu Jieping medical foundation | hepatocellular carcinoma | | | | |
| Recruiting | 2 | 69 | RoW | Regorafenib Pill&Camrelizumab | Nanfang Hospital of Southern Medical University, Jiangsu HengRui Medicine Co., Ltd. | Hepatocellular Carcinoma | 01/22 | 01/22 | | |
NCT02501551: Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy |
|
|
| Recruiting | 2 | 36 | RoW | regorafenib | Yonsei University | Melanoma | 05/22 | 06/22 | | |
| Completed | 2 | 95 | Europe, Japan, US, RoW | Pembrolizumab, Keytruda / MK-3475, Regorafenib (Stivarga, BAY73-4506) | Bayer, Merck Sharp & Dohme LLC | Hepatocellular Carcinoma | 05/22 | 04/24 | | |
NCT05130021: A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 130 | RoW | MAX-40279-01, regorafenib | Maxinovel Pty., Ltd. | Metastatic Colorectal Cancer | 05/22 | 10/23 | | |
NCT03520842: Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 22 | US | Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Regorafenib, BAY 73-4506, Stivarga | Stanford University | KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7 | 06/22 | 06/22 | | |
| Recruiting | 2 | 120 | Europe | Regorafenib, stivarga, placebo | Gruppo Oncologico Italiano di Ricerca Clinica | Gastric Cancer | 06/22 | 12/22 | | |
ChiCTR2000033070: A Multicenter, Open-Label, Single-Arm Phase II Trial to Evaluate the Efficacy and Safety of Capecitabine /Oxaliplatin (XELOX Regimen) in Combination with Regorafenib and PD-1 Monoclonal Antibody in First-line Treatment of Patients with HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 73 | | Capecitabine/Oxaliplatin (XELOX Regimen) in Combination with Regorafenib and PD-1 Monoclonal Antibody | Shanghai Oriental Hospital; Shanghai Oriental Hospital, East Clinical Center of Oncology, ECCO | HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | | | | |
NCT05289726: Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105 |
|
|
| Not yet recruiting | 2 | 152 | RoW | Traditional chinese medicine TDX105, Placebo | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Hand and Foot Skin Reaction, Colorectal Cancer Stage IV | 07/22 | 04/23 | | |
TRAP study, NCT04483219: Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. |
|
|
| Recruiting | 2 | 53 | RoW | TKI ± anti-PD-1 antibody | China Medical University, China | MSS, pMMR, Metastatic Colorectal Adenocarcinoma | 07/22 | 07/22 | | |
NCT05135364: HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure |
|
|
| Recruiting | 2 | 48 | RoW | Camrelizumab, HAIC, TKI | Yue Han, Jiangsu HengRui Medicine Co., Ltd. | Unresectable Hepatocellular Carcinoma | 10/22 | 12/24 | | |
RAIR DTC, NCT02657551: A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer |
|
|
| Active, not recruiting | 2 | 8 | US | Regorafenib, Stivarga | Dana-Farber Cancer Institute, Bayer | Thyroid Cancer | | | | |
Regosinti, NCT04745130: Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 90 | RoW | Sintilimab，regofinib，cetuximab, KRAS BRAF mutant Sintilimab + regafinil | Tianjin Medical University Cancer Institute and Hospital | Sintilimab, Cetuximab, Regorafenib,Combine,mCRC | 02/23 | 01/24 | | |
NCT04030260: Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 28 | RoW | Regorafenib and PD-1 antibody in Combination with Radiotherapy, Regorafenib, PD-1 antibody, Radiation therapy | Sun Yat-sen University | Colorectal Cancer Metastatic, MSS | 02/23 | 07/23 | | |
NCT03890731 / 2018-003650-24: A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed |
|
|
| Completed | 2 | 6 | Europe, Japan, US | BAY73-4506 (Regorafenib, Stivarga), Tyrosine-kinase inhibitor | Bayer | Solid Cancer | 02/23 | 02/23 | | |
NCT04704154 / 2020-003359-13: A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors |
|
|
| Active, not recruiting | 2 | 175 | Europe, Japan, US, RoW | Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo) | Bayer, Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd | Solid Tumors | 03/23 | 03/24 | | |
ChiCTR2000031237: Phase II clinical study of advanced PMMR colorectal cancer treated by cindilimab and regofinib combinating radiotherapy and Stereotactic therapy |
|
|
| Not yet recruiting | 2 | 32 | | Sintilimab and Regorafenib plus Stereotactic Radiotherapy | Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen Center, No | Colorectal Cancer | | | | |
| Recruiting | 2 | 45 | RoW | HAIC-GEMOX+Cadonilimab+Regorafenib | Fudan University | Intrahepatic Cholangiocarcinoma | 05/25 | 05/26 | | |
NCT05730673: Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | | NA | 700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at week2, 160 mg Regorafenib at week 3 | CytoDyn, Inc., Amarex Clinical Research | CCR5, Microsatellite Stable, Metastatic, Colorectal Cancer | 05/23 | 08/23 | | |
REPROGRAM-01, NCT04534218: Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 49 | Europe | Regorafenib, Stivarga, Cyclophosphamide, Endoxan, Capecitabine, Xeloda, Aspirin, Kardegic | Centre Hospitalier Universitaire de Besancon, Bayer | Colo-rectal Cancer, Metastatic Cancer | 12/23 | 12/23 | | |
REGSIN, NCT04718909: Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC |
|
|
| Active, not recruiting | 2 | 166 | RoW | Regorafenib + sintilimab, Regorafenib | Second Affiliated Hospital of Guangzhou Medical University, ZhuHai Hospital, Shenzhen People's Hospital, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Zhaoqing, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guangxi Medical University, Jiangmen Central Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Peking University Shenzhen Hospital, Jieyang People's Hospital, Shantou Central Hospital, Yuebei People's Hospital, Zhaoqing Gaoyao People's Hospital | Hepatocellular Carcinoma Non-resectable | 07/23 | 12/23 | | |
NCT05485909: Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM |
|
|
| Recruiting | 2 | 32 | RoW | Radiofrequency ablation, Regorafenib and Toripalimab Combination | Sun Yat-sen University | Colorectal Cancer Liver Metastases | 07/23 | 06/24 | | |
CASTLE-03, NCT05057052: Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis |
|
|
| Recruiting | 2 | 25 | RoW | Sintilimab, Regorafenib, US/CT-guided Percutaneous Cryoablation | Fudan University | Liver Metastases, Colorectal Cancer Metastatic | 09/23 | 09/24 | | |
ChiCTR2100052072: A single arm, phase II study for Sintilimab for injection combined with Regorafenib tablets in the third or more line treatment of advanced colorectal cancer |
|
|
| Not yet recruiting | 2 | 50 | | Sintilimab and Regorafenib | Shanxi Cancer Hospital; Shanxi Cancer Hospital, Medical reimbursement and charitable drug donations | Colorectal cancer | | | | |
NCT04327700: Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib |
|
|
| Suspended | 2 | 25 | US | TheraBionic, Amplitude-modulated electromagnetic field device, Regorafenib, Stivarga | Wake Forest University Health Sciences, National Cancer Institute (NCI), THERABIONIC INC. | Hepatocellular Carcinoma | 05/25 | 11/25 | | |
NCT03944304: Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. |
|
|
| Recruiting | 2 | 40 | RoW | Paclitaxel | Asan Medical Center | Gastrointestinal Stromal Tumors | 11/25 | 11/25 | | |
NCT02023333: Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 11 | US | Regorafenib, BAY 73-45060 | Memorial Sloan Kettering Cancer Center, Bayer, State University of New York - Downstate Medical Center, Queens Cancer Center of Queens Hospital | Metastatic Colorectal Adenocarcinoma | 12/24 | 12/24 | | |
NCT04051606: Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma |
|
|
| Active, not recruiting | 2 | 14 | US | Regorafenib | Case Comprehensive Cancer Center | Recurrent Glioblastoma | 10/24 | 10/24 | | |
NCT05113368: Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer |
|
|
| Recruiting | 2 | 31 | US | Regorafenib, Fulvestrant | Sarah K. Lynam MD, Bayer | Ovarian Cancer, Serous Ovarian Cancer | 06/24 | 12/24 | | |
| Recruiting | 2 | 214 | Europe | Regorafenib, panitumumab, Panitumumab, regorafenib | Gruppo Oncologico del Nord-Ovest, Bayer, Amgen | Colorectal Cancer | 12/24 | 06/25 | | |
| Active, not recruiting | 2 | 78 | Europe, RoW | Regorafenib, imatinib, Glevec | Australasian Gastro-Intestinal Trials Group, European Organisation for Research and Treatment of Cancer - EORTC, Scandinavian Sarcoma Group | Gastrointestinal Stromal Tumour | 12/23 | 12/23 | | |
NCT03899428: Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC |
|
|
| Recruiting | 2 | 30 | RoW | Durvalumab, IMFINZI®, Sorafenib, Nexavar, BAY43-9006, Lenvatinib, Lenvima, E7080, Regorafenib, Stivarga, BAY73-4506, Cabozantinib, Cabometyx, XL184 | Humanity & Health Medical Group Limited | Hepatocellular Carcinoma | 12/25 | 12/25 | | |
PULSE, NCT03992456: Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 12 | US | Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Regorafenib, BAY 73-4506, Regorafenib Anhydrous, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 | Academic and Community Cancer Research United, National Cancer Institute (NCI) | Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma | 12/23 | 10/24 | | |
ChiCTR2200056067: HAIC Combined with Tislelizumab and Regorafenib for Advanced Intrahepatic Cholangiocarcinoma: A Single-Arm, Open-Label, Phase II Study |
|
|
| Not yet recruiting | 2 | 25 | China | HAIC + Tislelizumab + Regorafenib | The Fifth Medical Center of Chinese PLA General Hospital ; The Fifth Medical Center of Chinese PLA General Hospital, BeiGene, Ltd | Intrahepatic Cholangiocarcinoma | | | | |
| Recruiting | 2 | 30 | US | ECT204 T cells, Regorafenib (STIVARGA®, BAY73-4506) | Eureka Therapeutics Inc. | Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer | 12/26 | 12/26 | | |
| Active, not recruiting | 2 | 234 | Europe, US, RoW | Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care | Agenus Inc. | Metastatic Colorectal Cancer | 02/25 | 07/25 | | |
NCT06246643: A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies |
|
|
| Active, not recruiting | 2 | 13 | Europe, Japan, RoW | Regorafenib (Stivarga, BAY73-4506) | Bayer | Solid Malignant Tumors | 04/26 | 04/26 | | |
NCT04757363: A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer |
|
|
| Active, not recruiting | 2 | 39 | US | regorafenib, nivolumab, FOLFOX chemotherapy with oxaliplatin | Memorial Sloan Kettering Cancer Center, Bayer, Bristol-Myers Squibb | Esophagogastric Cancer, HER2-Negative | 02/25 | 02/25 | | |
NCT04775862: A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer. |
|
|
| Recruiting | 2 | 60 | RoW | investigator choice re-challenge with anti EGFR Rx | National Guard Health Affairs | Colon Cancer | 02/24 | 02/24 | | |
REVERCE II, NCT04117945: Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 22 | US | Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Irinotecan, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, MoAb ABX-EGF, Monoclonal Antibody ABX-EGF, Vectibix, Regorafenib, BAY 73-4506, Stivarga | Academic and Community Cancer Research United, National Cancer Institute (NCI) | BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8 | 02/24 | 03/25 | | |
NCT02098538: Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma |
|
|
| Active, not recruiting | 2 | 38 | US | Regorafenib | Memorial Sloan Kettering Cancer Center, Bayer | Adenoid Cystic Carcinoma | 03/25 | 03/25 | | |
| Active, not recruiting | 2 | 127 | Europe | Regorafenib, stivarga, Placebo | Centre Oscar Lambret | Metastatic Soft Tissue Sarcoma | 03/24 | 03/25 | | |
NCT04183088: Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 125 | RoW | Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2., Stivarga, BAY-73-4506, BGB-A317 | National Taiwan University Hospital, National Taiwan University Hospital, Yun-Lin Branch | Advanced Hepatocellular Carcinoma | 03/24 | 03/25 | | |
NCT05753163: Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study |
|
|
| Recruiting | 2 | 44 | RoW | HAIC-FOLFOX combined with Sintilimab and Regorafenib | Fudan University | Colorectal Liver Metastasis | 03/24 | 03/25 | | |
NCT05524155: Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis |
|
|
| Not yet recruiting | 2 | 30 | NA | HAIC, Hepatic Artery Infusion Chemotherapy, Sintilimab, IBI308, Regorafenib | Tianjin Medical University Cancer Institute and Hospital | Colorectal Cancer, Liver Metastasis | 03/24 | 12/24 | | |
VIVA, NCT05382741: Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): Trial |
|
|
| Recruiting | 2 | 182 | Europe | Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Imfinzi, Regorafenib 30 mg capsules, Stivarga | Ospedale Policlinico San Martino, Associazione Italiana per la Ricerca sul Cancro, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente, Bayer | Colorectal Cancer Stage IV, No Evidence of Disease State | 03/24 | 03/24 | | |
NCT06280105: A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib |
|
|
| Not yet recruiting | 2 | 40 | RoW | Cadonilimab+regorafenib | Meng Chao Hepatobiliary Hospital of Fujian Medical University | Hepatocellular Carcinoma | 03/26 | 03/27 | | |
NCT05278351: Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC |
|
|
| Recruiting | 2 | 87 | RoW | Tislelizumab Combined With Cetuximab and Irinotecan, TEC, Third-line regimens | Shanghai Zhongshan Hospital | Colorectal Neoplasms Malignant | 04/24 | 12/25 | | |
NCT06322563: Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC |
|
|
| Not yet recruiting | 2 | 20 | RoW | LTC004+regorafenib | Tianjin Medical University Cancer Institute and Hospital | Advanced/Metastatic Colorectal Cancer | 03/25 | 03/25 | | |
NCT06356584: Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 141 | RoW | Sintilimab | Shandong Cancer Hospital and Institute | Colorectal Cancer, Immunotherapy, Radiotherapy, Targeted Therapy | 10/26 | 10/26 | | |
ChiCTR2100045144: Prospective, single-arm clinical study of hepatic arterial infusion chemotherapy (HAIC) in combination with regorafenib and camrelizumab for second-line treatment of hepatocellular carcinoma previously treated with TKI |
|
|
| Recruiting | 2 | 38 | | HAIC+regorafenib+camrelizumab | Department of Hepatobiliary Surgery, Xinqiao Hospital, Army Medical University, Chongqing 400037, China; The Second Affiliated Hospital of Army Medical University, self-raised | HCC | | | | |
SLOT, NCT05963490: Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 90 | RoW | Regorafenib, Stivarga, Toripalimab, High/low-dose radiotherapy | Fudan University | Microsatellite Stable Metastatic Colorectal Cancer | 04/24 | 04/26 | | |
HCC-HAIC-001, NCT06375317: HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure |
|
|
| Not yet recruiting | 2 | 42 | NA | PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets | Yehua Shen | HCC - Hepatocellular Carcinoma | 04/26 | 10/26 | | |
| Active, not recruiting | 2 | 48 | US | Regorafenib 40 MG, Regorafenib 20MG, Nivolumab | Sarcoma Alliance for Research through Collaboration | Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Osteosarcoma Metastatic | 05/24 | 06/26 | | |
NCT05894837: Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases |
|
|
| Not yet recruiting | 2 | 30 | RoW | Serplulimab+Regorafenib, Hepatic Artery Bicarbonate Infusion | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer, Liver Metastases | 06/24 | 06/25 | | |
NCT06455254: Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM |
|
|
| Not yet recruiting | 2 | 44 | RoW | Candonilimab (AK104), Regorafenib | Jin-hong Chen | CRC | 12/25 | 06/26 | | |
| Not yet recruiting | 2 | 104 | Europe | Regorafenib 40 MG Oral Tablet, Local Standard of Care | Istituto Oncologico Veneto IRCCS, Bayer | Meningioma, Malignant | 12/26 | 03/27 | | |
ChiCTR2200058068: A clinical study of tislelizumab combined with rigofenib and arterial perfusion chemotherapy in the first line of treatment of advanced cholangiocarcinoma |
|
|
| Not yet recruiting | 2 | 40 | China | tislelizumab combined with rigofenib and arterial perfusion chemotherapy | The First Affiliated Hospital of Zhengzhou University ; The First Affiliated Hospital of Zhengzhou University, self-funded | cholangiocarcinoma | | | | |
NCT06089330: A Study of JMT101 in Patients With Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 102 | NA | JMT101, SG001, Irinotecan, Regorafenib (Stivarga) | Shanghai JMT-Bio Inc. | Metastatic Colorectal Cancer (mCRC) | 07/24 | 12/24 | | |
NCT05877001: The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases |
|
|
| Recruiting | 2 | 20 | RoW | Tislelizumab, BGB-A317, Regorafenib, BAY73-4506, HAIC | Peking University Cancer Hospital & Institute | Colorectal Liver Metastases | 07/24 | 03/25 | | |
| Not yet recruiting | 2 | 28 | RoW | Liporaxel | Asan Medical Center | Gastrointestinal Stromal Tumors | 03/27 | 03/27 | | |
SINCERE, NCT05933980: Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 44 | RoW | Rego+Tori+Cele, Bayer AG, Innovent Biologics | Sun Yat-sen University | Colorectal Cancer, Liver Metastases, MSS | 09/25 | 12/25 | | |
TACT-D, NCT03844620: Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 100 | US | Best Practice, standard of care, standard therapy, Laboratory Procedure, Lab Test, Lab Tests, Laboratory Test, Test, Tests, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Regorafenib, BAY 73-4506, Stivarga, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8 | 08/24 | 08/24 | | |
NCT05820906: Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Cadonilimab+Regorafenib+GC | Tianjin Medical University Cancer Institute and Hospital | Advanced Biliary Tract Cancer | 09/24 | 09/25 | | |
CARE, NCT06425133: Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers |
|
|
| Not yet recruiting | 2 | 174 | Europe | Blood sample, Quality of life questionnaires, Biopsy, Regorafenib, Regorafenib + metronomic chemotherapy | Centre Hospitalier Universitaire de Besancon, Groupement Interrégional de Recherche Clinique et d'Innovation | Metastatic Colorectal Cancer | 09/27 | 09/28 | | |
NCT05535647: Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Not yet recruiting | 2 | 60 | RoW | Regorafenib and HAIC, FOLFOX | Tianjin Medical University Cancer Institute and Hospital | Intrahepatic Cholangiocarcinoma | 09/24 | 09/25 | | |
ChiCTR2100049343: Chemotherapy combined with tislelizumab combined with regorafenib combined with granulocyt-macrophage colony stimulating factor in a one-arm, exploratory clinical study for neoadjuvant therapy for resectable or borderline resectable pancreatic cancer: a single-arm, exploratory clinical study |
|
|
| Not yet recruiting | 2 | 30 | China | AG (albumin paclitaxel plus gemcitabine) regimen chemotherapy combined with tislelizumab plus regorafenib combined with granulocyt-macrophage colony colony | The First Affiliated Hospital of Soochow University ; The First Affiliated Hospital of Soochow University, BeiGene (Beijing) Biotechnology Co., Ltd. provides Tislelizumab | resectable or borderline resectable pancreatic cancer | | | | |
ChiCTR2100049459: Gemcitabine combined with Regorafenib and granulocyte-macrophage colony stimulating factor (GM-CSF) combined with Sintilimab combined with or without IBI310, a two-arm, open, exploratory phase II clinical study for first-line treatment of advanced pancreatic cancer |
|
|
| Not yet recruiting | 2 | 60 | | gemcitabine combined with Sintilimab combined with IBI310 combined with regofinib combined with GM-CSF ;gemcitabine combined with Sintilimab combined with regofinib combined with GM-CSF | First Affiliated Hospital of Soochow University; First Affiliated Hospital of Soochow University, Innovent will offer Sintilimab as well as IBI301 | advanced pancreatic cancer | | | | |
| Active, not recruiting | 2 | 40 | RoW | regorafenib | CHA University, Bayer | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
ChiCTR2300071355: AK104 combined with regorafenib for third-line and above treatment of pMMR/MSS advanced colorectal cancer |
|
|
| Recruiting | 2 | 30 | | Cadonilimab in combination with regorafenib | National Cancer Center/Chinese Academy of Medical Sciences; National Cancer Center/Chinese Academy of Medical Sciences, No | pMMR/MSS advanced colorectal cancer | | | | |
| Active, not recruiting | 2 | 46 | Europe | regorafenib | National Cancer Institute, Naples | Advanced Colorectal Cancer | 11/24 | 11/24 | | |
SOREGATT, NCT04450836: Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 340 | Europe | Regorafenib then Trifluridine/Tipiracil, STIVARGA, LONSURF, Trifluridine/Tipiracil then Regorafenib | UNICANCER | Metastatic Colorectal Cancer | 11/24 | 05/28 | | |
NCT05472948: Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | Surufatinib, SULANDA, Sintilimab, IBI308, Capecitabine, Capecitabine tablets | Sun Yat-sen University | Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic | 11/24 | 11/25 | | |
| Recruiting | 2 | 48 | Europe | Regorafenib 40 MG Oral Tablet, Triplet therapy | Universitair Ziekenhuis Brussel | Melanoma Stage III, Melanoma Stage IV | 12/24 | 03/25 | | |
NCT05194293: Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer |
|
|
| Recruiting | 2 | 30 | US | Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Regorafenib, BAY 73-4506, Regorafenib Anhydrous | Academic and Community Cancer Research United, National Cancer Institute (NCI) | Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | 12/24 | 12/28 | | |
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer |
|
|
| Recruiting | 2 | 3791 | US | Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi | American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc. | Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors | 12/24 | 12/25 | | |
NCT02955940: An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib |
|
|
| Active, not recruiting | 2 | 10 | Europe, US | Ruxolitinib, INCB018424, Jakafi®, Capecitabine, Xeloda®, Regorafenib, Stivarga® | Incyte Corporation | Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer | 12/24 | 12/24 | | |
RX-CROME, NCT05900648: Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy |
|
|
| Withdrawn | 2 | 16 | NA | Regorafenib, BAY 73-4506, XmAb20717 | M.D. Anderson Cancer Center, Xencor, Inc., Bayer | Colorectal Cancer, Colon Cancer, Rectum Cancer | 02/24 | 02/24 | | |
| Active, not recruiting | 2 | 72 | Europe | Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy, Surgery, Non-operative Management | Jules Bordet Institute | Rectal Cancer Stage II, Rectal Cancer Stage III | 01/25 | 01/30 | | |
